Obesity, Renin-Angiotensin System Blockade and Risk of Adverse Renal Outcomes: A Population-Based Cohort Study.

CONCLUSION: This study, conducted in a large real-world cohort, provides evidence that RAS blockade may not provide benefit with regard to longitudinal renal outcomes in obese, hypertensive patients. Further research is needed to elucidate the hemodynamic and renoprotective role of antihypertensive medications in obese patients. PMID: 27228992 [PubMed - as supplied by publisher]

http://www.ncbi.nlm.nih.gov/pubmed/27228992?dopt=Abstract

Source: American Journal of Nephrology - May 27, 2016 Category: Urology & Nephrology Authors: Cohen JB, Stephens-Shields AJ, Denburg MR, Anderson AH, Townsend RR, Reese PP Tags: Am J Nephrol Source Type: research